About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Pulmonary Mucormycosis and Cytomegalovirus Co-Infection in a Renal Transplant Recipient

how much does abortion cost

buy abortion pill
Gayathri Devi HJ, Mahesh E1, Sulatha M Kamath2, Jayanth K Das3
From the Department of Chest Diseases, Nephrology1, Pathology2: MS Ramaiah Medical College, Bangalore & Department of Cardiothoracic surgery3, MS Ramaiah Narayana Hrudayalaya, Bangalore-560054, India.
Corresponding Author:
Dr. Gayathri Devi HJ
Email: joshyev@gmail.com
Received: 14-JAN-2013 Accepted: 25-JAN-2013 Published Online: 25-FEB-2013
DOI: http://dx.doi.org/10.17659/01.2013.0019
Abstract
Early detection and effective treatment of opportunistic infections in immune-suppressed renal transplant patients are a part of a renal transplant programme. We are reporting a successfully treated case of concomitant pulmonary mucormycosis and cytomegalovirus (CMV) in a patient who had undergone renal transplant, twice.
Keywords : Mucormycosis, Cytomegalovirus, Kidney, Kidney Transplantation, Opportunistic Infections.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Dec 04, 2024